CAJ | 학술논문

脉络膜新生血管(CNV)是多种致盲眼病包括年龄相关性黄斑变性等的主要致盲原因.由于疾病的自身特性以及眼屏障的存在使得CNV的治疗成为一个棘手的问题.目前基因治疗是一种新的治疗方向,随着分子材料学的进展,纳米粒子成为一种极具前景的基因治疗载体.纳米粒子,特别是聚乳酸(PLA)及与聚乙醇酸(PGA)的共聚物(PLGA)纳米粒子具有良好的组织相容性及生物可降解性,可安全长效地介导体内、外视网膜色素上皮细胞的特异性转染.目前采用纳米粒子携带治疗基因通过偶联特异性配体等方式,主要通过玻璃体腔或全身静脉注射两种给药途径,可安全有效地抑制实验性CNV.
맥락막신생혈관(CNV)시다충치맹안병포괄년령상관성황반변성등적주요치맹원인.유우질병적자신특성이급안병장적존재사득CNV적치료성위일개극수적문제.목전기인치료시일충신적치료방향,수착분자재료학적진전,납미입자성위일충겁구전경적기인치료재체.납미입자,특별시취유산(PLA)급여취을순산(PGA)적공취물(PLGA)납미입자구유량호적조직상용성급생물가강해성,가안전장효지개도체내、외시망막색소상피세포적특이성전염.목전채용납미입자휴대치료기인통과우련특이성배체등방식,주요통과파리체강혹전신정맥주사량충급약도경,가안전유효지억제실험성CNV.
Choroidal neovascularization(CNV)is the main cause of severe visual impairment in many blindness-leading diseases,including age-related macular degeneration(AMD).At present,treatment for CNV is still a challenging work since drug delivery may be limited to the retinal pigment epithelium(RPE)and choroid because of several formidable barriers.In this article,we reviewed the properties of nanoparticles,and recent substantial progress in the development of nanoparticles as a targeted vector of gene therapy for CNV,which is a promising approach to provide safe and long-term gene expression to inhibit experimental CNV.